Non-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies

Cancer Treatment Reviews

Volumn 29, Issue 4, 2003, Pages 283-290

  Mielcarek, Marco ^a,b   Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Canine transplant model; Graft versus tumor effects; Hematologic malignancies; Hematopoiesis; Non myeloablative transplantation; Regimen related toxicities

Indexed keywords

CYCLOSPORIN; CYTOTOXIC AGENT; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE LEUKEMIA; ADULT; AGED; BLOOD DISEASE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHIMERA; CHRONIC LEUKEMIA; DOG; DRUG MEGADOSE; DRUG POTENTIATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MYELODYSPLASIA; MYELOMA; MYELOPROLIFERATIVE DISORDER; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHENOTYPE; REVIEW; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT PLANNING; WHOLE BODY RADIATION;

EID: 0042912907     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00004-5     Document Type: Article

References (44)

1. Thomas ED, Blume KG, Forman SJ (eds.), Hematopoietic Cell Transplantation. 2nd edn. Blackwell Science: Boston, 1999.
2. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD. Bone-marrow transplantation. N Engl J Med 1975; 292: 832-843, 895-902.
3. Fefer A, Sullivan KM, Weiden P, Buckner CD, Schoch G, Storb R, Thomas ED. Graft versus leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. In: Truitt RL, Gale RP, Bortin MM (eds.), Cellular Immunotherapy of Cancer. Alan R. Liss: New York, 1987; 401-408.
4. Zittoun RA, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans ME, Dardenne M, Vegna ML, Petti MC, Solbu G, Suciu S. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217-223.
5. Gorin NC, Labopin M, Fouillard L, Meloni G, Frassoni F, Iriondo A, Brunet MS, Goldstone AH, Harousseau JL, Reiffers J, Esperou-Bourdeau H, Gluckman E. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. Bone Marrow Transplant 1996; 18: 111-117.
6. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
7. Butturini A, Bortin MM, Gale RP. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant 1987; 2: 233-242.
8. Ringden O, Horowitz MM. Graft-versus-leukemia reactions in humans. Transplant Proc 1989; 21: 2989-2992.
9. Sullivan KM, Fefer A, Witherspoon R, Storb R, Buckner CD, Weiden P, Schoch G, Thomas ED. Graft-versus-leukemia in man: Relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. In: Truitt RL, Gale RP, Bortin MM (eds.), Cellular Immunotherapy of Cancer. Alan R. Liss: New York, 1987; 391-399.
10. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Sanders J, Singer J, Stewart P, Thomas ED. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
11. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068-1073.
12. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533.
13. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
14. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM, Flombenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
15. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, De Witte T, Holler E, Ansari H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. european group for blood and marrow transplantation working party chronic leukemia. Blood 1995; 86: 2041-2050.
16. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
17. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100-106.
18. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NC, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
19. Storb R, Yu C, McSweeney P. Mixed chimerism after transplantation of allogeneic hematopoietic cells. In: Thomas ED, Blume KG, Forman SJ (eds.), Hematopoietic Cell Transplantation. 2nd edn. Blackwell Science: Boston, 1999; 287-295.
20. Yu C, Storb R, Mathey B, Deeg HJ, Schuening FG, Graham TC, Seidel K, Burnett R, Wagner JL, Shulman H, Sandmaier BM. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 1995; 86: 4376-4381.
21. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, Leisenring W, Shulman H. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
22. Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, Santos E, Storb R. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 1998; 91: 2581-2587.
23. Storb R, Yu C, Barnett T, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, McSweeney P, Seidel K, Georges G, Zaucha JM. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999; 94: 1131-1136.
24. Georges GE, Storb R, Thompson JD, Yu C, Gooley T, Bruno B, Nash RA. Adoptive immunotherapy in canine mixed chimeras after non-myeloablative hematopoietic cell transplantation. Blood 2000; 95: 3262-3269.
25. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
26. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers MED, Georges GE, Grumet FC, Kiem H-P, Torok-Storb B, Yu C, Blume KG, Storb RF. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
27. McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications (Review). Biol Blood Marrow Transplant 1999; 5: 192-203.
28. Sandmaier BM, Maloney DG, Gooley T, Hegenbart U, Shizuru J, Sahebi F, Chauncey T, Agura E, Bruno B, McSweeney P, Forman S, Blume K, Niederwieser D, Storb R. Non-myeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: clinical results of a TBI-based conditioning regimen. Blood 2001; 98(Part 1): 742a-743a, #3093 (Abstract).
29. Sandmaier BM, Maloney DG, Gooley TA, Shizuru J, Hegenbart U, Sahebi F, Chauncey T, Bruno B, Agura E, McSweeney P, Forman S, Niederwieser D, Blume K, Storb R. Low dose TBI conditioning for hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: influence of fludarabine or cytoreductive autografts on outcome. Blood 2002; 100(Part 1), 145a, #544 (Abstract).
30. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving non-myeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001; 98: 3584-3588.
31. Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Storb R. Incidence and outcome of bacterial and fungal infections following non-myeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8: 512-520.
32. Junghanss C, Marr KA. Infectious risks and outcomes after stem cell transplantation: are non-myeloablative transplants changing the picture?. Curr Opin Inf Dis 2002; 15: 47-353.
33. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Little M-T, Corey L, Storb R. Incidence and outcome of cytomegalovirus infections following non-myeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-1985.
34. Mielcarek M, Martin PJ, Leisenring W, Flowers MED, Maloney D, Sandmaier B, Maris M, Storb R. Graft-versus-host disease after non-myeloablative versus conventional hematopoietic stem cell transplantation. Blood 2002; 100(Part 1): 175a, #656 (Abstract).
35. Niederwieser D, Maris M, Hegenbart U, Sandmaier B, McSweeney P, Pönisch W, Uharek L, Deininger M, Edelmann J, Kamprath F, Shizuru JA, Blume K, Storb R. Allogeneic unrelated hematopoietic stem cell transplants (HSCT) after conditioning with 2Gy total body irradiation (TBI), fludarabine (FLU) and a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) in patients ineligible for conventional transplants. Blood 2000; 96(Part 1): 413a, #1778(Abstract).
36. Maris M, Niederwieser D, Sandmaier B, Maloney D, Shizuru J, Petersdorf E, Blume K, Chauncey T, Pulsipher M, McSweeney P, Storer B, Anasetti C, Woolfrey A, Slattery J, Agura E, Little M-T, Hegenbarth U, Storb R. Non-myeloablative hematopoietic stem cell transplants (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT. Blood 2001; 98(Part 1): 858a, #3563 (Abstract).
37. Maris MB, Niederwieser D, Sandmaier BM, Maloney DG, Shizuru J, Petersdorf E, Storer B, Pulsipher M, McSweeney P, Slattery J, Woolfrey A, Agura E, Chauncey T, Little M-T, Hegenbarth U, Anasetti C, Blume K, Storb R. Non-myeloablative hematopoietic stem cell transplants (NM-HSCT) using 10 HLA antigen matched unrelated donors (URDs) for patients (pts) with advanced hematologic malignancies. Blood 2002; 100(Part 1): 76a, #275 (Abstract).
38. Maloney DG, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Molina AJ, Bensinger W, McSweeney PA, Storer BE, Niederwieser D, Chauncey T, Appelbaum FR, Blume KG, Forman SJ, Storb R. Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Blood 2001; 98(Part 1): 434a-435a, #1822 (Abstract).
39. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
40. Zaucha JM, Mielcarek M, Storb R, Zellmer E, Torok-Storb B. G-CSF mobilized peripheral blood mononuclear cells facilitate the development of stable mixed hematopoietic chimerism in dogs conditioned with only 100cGy of irradiation. Blood 1999; 94(Suppl 1): 319a, #1425 (Abstract).
41. Zaucha JM, Zellmer E, Georges G, Little M-T, Storb R, Storer B, Torok-Storb B. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in non-myeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant 2001; 7: 613-619.
42. Saito K, Sakurai J, Ohata J, Kohsaka T, Hashimoto H, Okumura K, Abe R, Azuma M. Involvement of CD40 ligand-CD and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J Immunol 1998; 160: 4225-4231.
43. Yu XZ, Bidwell SJ, Martin PJ, Anasetti C. CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol 2000; 164: 4564-4568.
44. Storb R, Yu C, Zaucha JM, Deeg HJ, Georges G, Kiem H-P, Nash RA, McSweeney PA, Wagner JL. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999; 94: 2523-2529.